Stellar Biotechnologies Announces Retention of LifeTech Capital for Strategic Business Planning
September 12, 2011
PORT HUENEME, CA (September 12, 2011) -- Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have entered into an agreement for strategic business planning advisory services with LifeTech Capital ("LifeTech" a division of Aurora Capital LLC – (http://LifeTechCapital.com) of Boca Raton, San Francisco and New York. Under the agreement, LifeTech will provide Stellar with advisory services, including, but not limited to, issues related to input on market landscape, as well as strategic business and product planning.
LifeTech Capital is a boutique specialty firm, focused entirely on the life sciences industries: pharmaceuticals, biotechnology, medical diagnostics and devices.
About Stellar Biotechnologies, Inc. Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need.
Contact:
Darrell Brookstein
Executive VP, Corporate Development & Finance
322 Scott Street
Port Hueneme, CA 93041
(805) 488-2147 ext. 103
dbrookstein@stellarbiotech.com
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.
